Blessing, Carolyn A.

Carolyn A. Blessing

Partner
RELATED SERVICES

Carolyn Blessing concentrates her practice in IP Pharmaceutical matters and Hatch-Waxman litigation. She represents pharmaceutical and biotechnology companies in all aspects of federal intellectual property litigation, including pre-litigation activities, Paragraph IV Certifications, filing, fact and expert discovery, claim construction, motion practice, pre-trial, trial, post-trial and appellate phases. Carolyn is the law school Hiring Partner for the Chicago office.

Carolyn Blessing concentrates her practice in IP Pharmaceutical matters and Hatch-Waxman litigation. She represents pharmaceutical and biotechnology companies in all aspects of federal intellectual property litigation, including pre-litigation activities, Paragraph IV Certifications, filing, fact and expert discovery, claim construction, motion practice, pre-trial, trial, post-trial and appellate phases. Carolyn is the law school Hiring Partner for the Chicago office.

Prior to joining Locke Lord, Carolyn acted as lead associate for a family of four complex patent litigations involving both patent infringement and Hatch-Waxman litigation, and undertook substantial responsibility for drafting and filing court documents, coordinating large teams of attorneys and liaising with the client, co-counsel, opposing counsel and vendors on an extensive array of issues. She also assisted with all aspects of patent prosecution and counseling for biotechnology companies.

Before attending law school, Carolyn gained practical experience working as a neurobiologist for a major pharmaceutical company. While there, she participated in the investigation of multiple sclerosis treatments that focused on promoting and enhancing remyelination. During her undergraduate studies, she conducted senior thesis research and authored a literature study on nuclear Actin Related Proteins (ARPs) and organized and led a project to characterize novel ARP proteins in yeast cells. Additionally, she interned in a pharmaceutical laboratory where she designed and conducted a study of the cross-resistance of test mammalian cancer cell lines to nucleoside based drugs.

Carolyn’s representative experience includes:

Ongoing matters

  • Representing generic drug manufacturers in paragraph IV Hatch-Waxman patent infringement litigation concerning one patent related to a parenteral formulation for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery (Bridion®)
  • Representing generic drug manufacturers in paragraph IV Hatch-Waxman patent infringement litigation concerning four patents related to an oral formulation used for the symptomatic management of stable heart-related chest pain and heart failure not fully managed by beta blockers (Corlanor®)
  • Representing generic drug manufacturers in paragraph IV Hatch-Waxman patent infringement litigation concerning three patents related to an oral formulation for an atypical antipsychotic, which is used in the treatment of schizophrenia, bipolar mania and bipolar depression (Vraylar®)
  • Representing generic drug manufacturers in paragraph IV Hatch-Waxman patent infringement litigation concerning six patents related to an oral formulation for the treatment of irritable bowle syndrome with diarrhea (IBS-D) (Viberzi®)
  • Representing generic drug manufacturers in paragraph IV Hatch-Waxman patent infringement litigation concerning one patent related to oral formulations for the treatment of type 2 diabetes in adults (Januvia®, Janumet®, Janumet XR®)
  • Representing generic drug manufacturers in paragraph IV Hatch-Waxman patent infringement litigation concerning 10 patents related to an oral formulation for the treatment of certain types of psoriasis and psoriatic arthritis (Otezla®)
  • Representing generic drug manufacturers in paragraph IV Hatch-Waxman patent infringement litigation concerning five patents related to an oral formulation for the treatment of depression (Trintellix®)

Completed matters

  • Represented generic drug manufacturers in paragraph IV Hatch-Waxman patent infringement litigation concerning one patent related to an oral formulation for the treatment of multiple sclerosis (Gilenya®). Resolved matter through settlement
  • Represented generic drug manufacturers in paragraph IV Hatch-Waxman patent infringement litigation concerning two patents relating to an oral formulation for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) (Eliquis®). Resolved matter through settlement
  • Represented generic drug manufacturer in paragraph IV Hatch-Waxman patent infringement litigation concerning one patent relating to an oral formulation for the treatment of secondary hyperparathyroidism (HPT) (Sensipar®). Resolved matter through settlement
  • Represented generic drug manufacturer in paragraph IV Hatch-Waxman patent infringement litigation concerning four patents relating to an oral formulation for treating overactive bladder (OAB) (Myrbetriq®). Resolved matter through settlement
  • Represented generic drug manufacturer in paragraph IV Hatch-Waxman patent infringement litigation concerning three patents relating to an oral formulation for treating COPD (Daliresp®). Resolved matter through settlement
  • Represented generic drug manufacturer in paragraph IV Hatch-Waxman patent infringement litigation concerning two patents relating to a testosterone metered transdermal solution (Axiron®) and one patent relating to an applicator device, resulting in a district court verdict where all asserted formulation claims were found invalid and all asserted device claims were not infringed; on appeal, the Federal Circuit affirmed the judgment in its entirety
  • Represented generic drug manufacturer in paragraph IV Hatch-Waxman patent infringement litigation concerning three patents relating to extended-release capsules for treating certain types of seizures (Trokendi XR®). Resolved matter through settlement
  • Represented generic drug manufacturer in paragraph IV Hatch-Waxman patent infringement litigation concerning injectable antibiotic IV infusion (Tygacil®). Resolved matter through settlement
  • Represented generic drug manufacturer in paragraph IV Hatch-Waxman patent infringement litigation concerning oral formulations used to treat depression (Pristiq®). Resolved matter through settlement
  • Represented generic drug manufacturer in paragraph IV Hatch-Waxman patent infringement litigation concerning oral formulations used to treat ulcerative colitis (Asacol HD®). Resolved matter through settlement
  • At previous firm, represented a major pharmaceutical company in a Hatch-Waxman litigation concerning nine patents relating to one of their blockbuster brand-name drugs, resulting in a district court verdict where all asserted claims were found valid and enforceable and where defendants infringed all asserted claims
RELATED EXPERIENCE
RELATED EXPERIENCE
RELATED NEWS & EVENTS
CREDENTIALS
Education
  • J.D., University of Notre Dame Law School, 2008
    Journal of College and University Law, Executive Production Manager (2007-08)
    Intellectual Property Law Society, President (2007-08), Vice-President (2006-07)
  • B.S., Biochemistry, University of Notre Dame, 2004
  • B.A., English, University of Notre Dame, 2004
Bar Admissions
  • New York, 2009
  • District of Columbia, 2010
  • Illinois, 2013
Court Admissions
  • U.S. Court of Appeals for the Federal Circuit, 2009
  • U.S. District Court for the Eastern District of New York, 2009
  • U.S. District Court for the Southern District of New York, 2009
  • U.S. District Court for the Northern District of Illinois, 2017
Professional Affiliations
    • Richard Linn American Inn of Court
      • Secretary (2015-2016)
      • Dinner Chair (2014-2015)
    • Coalition of Women's Initiatives in Law
      • Secretary/Treasurer and Member, National Board
      • Board Liaison for Locke Lord
      • President, Chicago Chapter (2019)
      • Vice-President, Chicago Chapter (2018)
      • Recipient of the 2018 Coalition Leadership Award
      • Treasurer, Chicago Chapter (2016, 2017)
      • Co-Chair, Associates Committee of Chicago Chapter (2014-2016)
    • Chicago Women in IP (ChiWIP)
      • Mentorship Committee, Co-Chair
      • Outreach Committee (2017-2020)
      • Career Development Programs Committee (2016-2017)
      • Planning Committee (2015-2016)
    • Chicago Daily Law Bulletin and Chicago Lawyer Magazine Women’s Advisory Board
    • Federal Circuit Bar Association (2010-Present)
    • New York Intellectual Property Law Association
      • Co-Chair, Young Lawyers Committee (2011-2012)
      • Co-Chair, Women in IP Law Committee (2010-2011)
    • Hon. William C. Conner Inn of Court (2008-2012)
Awards & Recognitions
    • Named, 40 Under Forty, Chicago Lawyer and Chicago Daily Law Bulletin (2019)
    • Named, Emerging Lawyers℠, Biotechnology & Pharmaceutical, Intellectual Property and Patent Law (2020)
    • Named, Super Lawyers® Illinois Rising Star, Intellectual Property (2016-2019)
Community Leadership
    • St. Procopius Legal Clinic
      • Chair (2014-2016)
      • CVLS Distinguished Service Award (2016)
    • The Joffrey Ballet
      • Member, Joffrey Ambassadors
      • Co-Chair, Generation J Leadership Council
      • Joffrey Auxiliary Board; Co-Chair (2016-2018);
      • Membership Chair (2014-2016)
      • Host Committee Member, Joffrey Women’s Board Fall Luncheons (Swan Lake 2014; Sylvia 2015; Romeo and Juliet 2016)
    • Board Vice President, 137 Films (2013-Present)
    • Visionary Member, Step-Up (2013-Present)
Professional History
    • Associate, Locke Lord LLP (2012-2016)
    • Associate, Kenyon & Kenyon LLP (2008-2012)